Vcanbio Cell & Gene Engineering Corp., Ltd (SHA:600645)
China
· Delayed Price · Currency is CNY 30.79
-0.11 (-0.36%)
At close: Mar 9, 2026
SHA:600645 Revenue
Vcanbio Cell & Gene Engineering Corp., had revenue of 376.09M CNY in the quarter ending September 30, 2025, a decrease of -6.82%. This brings the company's revenue in the last twelve months to 1.47B, down -7.61% year-over-year. In the year 2024, Vcanbio Cell & Gene Engineering Corp., had annual revenue of 1.59B, down -0.27%.
Revenue (ttm)
1.47B
Revenue Growth
-7.61%
P/S Ratio
9.54
Revenue / Employee
730.87K
Employees
2,014
Market Cap
14.04B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.59B | -4.30M | -0.27% |
| Dec 31, 2023 | 1.59B | 34.84M | 2.24% |
| Dec 31, 2022 | 1.55B | 19.56M | 1.27% |
| Dec 31, 2021 | 1.54B | 216.43M | 16.41% |
| Dec 31, 2020 | 1.32B | -67.88M | -4.90% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tibet Cheezheng Tibetan Medicine | 2.42B |
| Pacific Shuanglin Bio-pharmacy | 2.38B |
| Inner Mongolia Furui Medical Science | 1.47B |
| Star Lake Bioscience Co., Inc.Zhaoqing Guangdong | 16.62B |
| Mabwell (Shanghai) Bioscience | 662.52M |
| InventisBio | 37.33M |
| Staidson (Beijing) BioPharmaceuticals | 244.37M |
| Anhui Anke Biotechnology (Group) | 2.58B |